They also found that tumor PD-L1 expression reflected an immune-active microenvironment, while it did so in association with other immunosuppressive molecules, including PD-1 and PD-L2, it was the single factor most closely correlated with response to anti-PD-1 mAbs in patients with melanoma, non-small cell lung carcinoma, renal cell carcinoma, CRC, or castration-resistant prostate cancer (57). The gene discussed is CD274; the disease is melanoma.